|
| [March 04, 2013] |
 |
Clearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial Operations
ALPHARETTA, Ga. --(Business Wire)--
Clearside Biomedical, Inc., a privately held ophthalmic company
developing and commercializing targeted therapeutics for the treatment
of sight-threatening diseases, today announced the appointment of
Stephen H. Lang as Vice President, Commercial Operations.
Lang has more than 30 years of experience in the ophthalmic
pharmaceutical industry, specializing in the areas of sales, marketing,
sales operations and business development.
"Steve's broad knowledge of ophthalmology and experience in building and
leading commercial teams in the U.S. along with his global experience
are invaluable assets to us," said Daniel White, president and CEO. "He
will be a very important part of the leadership team we are building at
Clearside Biomedical."
Lang served from 2006 until 2012 as Vice President, Sales, at ISTA
Pharmaceuticals, Inc., where he led the building and expansion of ISTA's
sales organization and exceeded US $160 million in annual sales.
Prior to joining ISTA, Lang was Senior Vice President, U.S. Sales and
Marketing, for Novartis Ophthalmics, Inc., where his team launched
Visudynereg; (Valeant Pharmaceuticals International, Inc.; NYSE: VRX).
Visudyne® was the first available drug therapy for people with a form of
age-related macular degeneration known as classic "wet AMD (News - Alert)." Before
joining Novartis, Lang served for more than 16 years in various
positions with Allergan, Inc. (NYSE: AGN), including sales, marketing,
national accounts and global business development. He obtained his
B.B.A. in Management from Georgia Southern University.
"I look forward to helping bring Clearside's breakthrough products to
market," said Lang, noting that the company's CLS1001 (triamcinolone
acetonide) Suprachoroidal Injectable Suspension is being developed to
treat sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids. "Using
our proprietary microinjection platform to deliver drugs to the back of
the eye via the suprachoroidal space holds great promise to help
millions of people suffering from debilitating eye diseases. We offer a
novel approach to posterior segment care that will be the foundation of
Clearside's commercial success."
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a
clinical-stage ophthalmic pharmaceutical company that develops and
commercializes targeted therapeutics to treat sight-threatening
diseases. Clearside treats the pathological changes to the blood retinal
barrier that lead to retinal blindness by delivering therapeutics
through the suprachoroidal space to the retina and choroid using a
proprietary microinjection dosage form. Clearside Biomedical was founded
by an executive team with extensive development and revenue growth
expertise. This team strives for better delivery and performance of its
therapeutic agents to improve the standard of care for patients with
retinal and choroidal disease. Visit www.clearsidebiomedical.com
for more information.
[ InfoTech Spotlight's Homepage ]
|
